CTRI/2010/091/002922招募中3 期
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Twice-Daily 0.01% Bimatoprost / 0.15% Brimonidine / 0.5% Timolol Ophthalmic Solution (Triple Combination) in Patients in India, Who Have Glaucoma or Ocular Hypertension With Elevated IOP, and are on Twice-Daily 0.2% Brimonidine / 0.5% Timolol Ophthalmic Solution (Dual Combination) Therapy
Allergan India Private Limited, Level 2, Prestige Obelisk, No. 3 Kasturba Road, Bangalore, Karnataka, IndiaAllergan, Inc., Irvine, California, USA0 个研究点目标入组 120 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Glaucoma and/or ocular hypertension in both eyes
- •-Requires IOP-lowering treatment in both eyes
排除标准
- •-Other active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye)
- •-Required chronic use of ocular medications other than study medications, except for intermittent use of artificial tears
- •-Use of oral, injectable or topical corticosteroids within 21 days
- •-Any eye laser surgery within 3 months
- •-Any intraocular surgery (eg, cataract surgery) within 6 months
研究者
相似试验
进行中（未招募）
1 期
Safety and diagnostic Efficacy of Mangoral in Patients with abnormal liver cells and reduced kidney functioMRI in terms of visualization of detected focal liver lesions in patients with known or Suspected focal liver lesions and severe renal impairmentMedDRA version: 22.1Level: LLTClassification code 10028049Term: MRISystem Organ Class: 100000004848EUCTR2019-001599-12-ITAscelia Pharma AB197
进行中（未招募）
1 期
A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with Known or Suspected Focal Liver Lesions and Severe Renal ImpairmentEUCTR2019-001599-12-SEAscelia Pharma AB197
进行中（未招募）
1 期
A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with Known or Suspected Focal Liver Lesions and Severe Renal ImpairmentMRI in terms of visualization of detected focal liver lesions in patients with known or Suspected focal liver lesions and severe renal impairmentMedDRA version: 22.1Level: LLTClassification code 10028049Term: MRISystem Organ Class: 10022891 - InvestigationsEUCTR2019-001599-12-DEAscelia Pharma AB197
进行中（未招募）
1 期
A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with Known or Suspected Focal Liver Lesions and Severe Renal ImpairmentEUCTR2019-001599-12-PLAscelia Pharma AB200
招募中
2 期
A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)fetal blood-disorder100381581000533010000211NL-OMON52622Janssen-Cilag International, NV1